POLARIS Progress in Leukodystrophies: Advance, Rate and Implement new treatment Strategies
- Coordinator
- Stichting Amsterdam Umc, Netherlands
- Runs
- 1 October 2026 to 30 September 2030
- Status
- Running
- EU funding
- €4.6m
- Total cost
- —
- Partners
- 32 organisations in 12 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101311855
What the project is doing
In the project's own words, from its summary on CORDIS.
Leukodystrophies are severe genetic disorders of the brain white matter that cause profound disability and premature death, mostly in children, and lack effective treatments. POLARIS aims to accelerate therapy development by training the next generation of leukodystrophy scientists capable of collaborating across the full spectrum of discovery, development, evaluation and implementation of innovative and accessible therapies.
Researchers will develop gene-therapy approaches (RO1), pharmacological strategies (RO2) and treatment-evaluation tools (RO3) to advance therapies for leukodystrophies and strengthen R&I frameworks for other rare diseases. A key barrier to progress is fragmentation: discovery, preclinical development, outcome definition and regulatory pathways rarely coexist in a single environment. POLARIS bridges this through 3 cross-cutting themes: (I) Affordable, Accessible and Timely—embedding cost, accessibility and real-world feasibility from the earliest stages; (II) Relevant Outcomes—focusing on what matters to patients, caregivers, clinicians, regulators and society; and (III) Transferable Knowledge & Tools—producing broadly applicable insights and platforms beyond individual diseases.
The programme integrates all relevant stakeholders, including strong engagement of patient organisations, industry and public bodies. POLARIS generates major scientific advances through innovative gene-therapy and pharmacological platforms, validated biomarkers and harmonised outcome measures that directly support future clinical trials. Its end-to-end translational pipeline creates scalable technologies relevant to a wide range of rare neurological disorders.
POLARIS enhances researchers’ career prospects, skills, employability and contributions to Europe’s innovation capacity. By reducing development barriers and enabling more effective, affordable treatments, POLARIS delivers substantial economic and societal benefits for patients, families and healthcare systems.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Coordinator |
| Vrije Universiteit Brussel | Bruxelles / Brussel | Belgium | Participant |
| Universitat Zurich | Zurich | Switzerland | Participant |
| Kypriako Idryma Erevnon Gia Ti Myiki Distrofia | Agios Dometios | Cyprus | Participant |
| Data Powered Therapeutics GmbH | Göttingen | Germany | Associatedpartner |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Enamine Germany GmbH | Frankfurt am Main | Germany | Associatedpartner |
| Fundacio Institut Hospital Del Mar D Investigacions Mediques | Barcelona | Spain | Participant |
| Universidad Pompeu Fabra | Barcelona | Spain | Associatedpartner |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Oulun Yliopisto | Oulu | Finland | Associatedpartner |
| Institut Du Cerveau Et De La Moelle Epiniere | Paris | France | Participant |
| Sorbonne Universite | Paris | France | Associatedpartner |
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Associatedpartner |
| Istituto Superiore Di Sanita | Roma | Italy | Participant |
| Universita Degli Studi Di Roma La Sapienza | Roma | Italy | Associatedpartner |
| ELA International | Luxembourg | Luxembourg | Associatedpartner |
| Agentschap College Ter Beoordeling Van Geneesmiddelen | Utrecht | Netherlands | Participant |
| Fundament Subsidieadvies | Hilversum | Netherlands | Associatedpartner |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Synaptologics BV | Leiden | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Associatedpartner |
| Vereniging Innovatieve Geneesmiddelen | Den Haag | Netherlands | Associatedpartner |
| Alex, The Leukodystrophy Charity | London | United Kingdom | Associatedpartner |
| Orchard Therapeutics (Europe) Limited | London | United Kingdom | Associatedpartner |
| The Anna Freud Centre | London | United Kingdom | Associatedpartner |
| The University of Liverpool | Liverpool | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Participant |
| University of Newcastle Upon Tyne | Newcastle Upon Tyne | United Kingdom | Associatedpartner |
| University of York | York North Yorkshire | United Kingdom | Participant |
| Zantiks Limited | Royston | United Kingdom | Associatedpartner |
| Alliance MLC Foundation | Middletown, DE | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI